Tempus AI agrees to buy Personalis for USD 16.25 per share in USD 1.5 billion deal
TEM•Closing timing and strategic rationale
Closing is expected in late 2026 or early 2027, pending Personalis shareholder vote and regulatory clearances.
The transaction expands Tempus’ minimal residual disease offering via Personalis’ tumor-informed NeXT Personal test; Personalis posted Q2 revenue of USD 22.4 million on 10,384 clinical tests.
Tempus AI to acquire Personalis in stock deal
Tempus AI agreed to acquire Personalis for USD 16.25 per share, valuing the deal at USD 1.5 billion net of Tempus’ existing stake.
Consideration is 100% stock, with an option to pay up to 50% in cash at Tempus’ discretion; cash would use cash on hand and credit facilities.
Personalis holders will receive a floating exchange ratio of Tempus Class A common stock, capped at 0.3356 per Personalis share.
